Eli Lilly CEO: 700,000 Seniors Begin GLP-1s Under Medicare Coverage
Eli Lilly's CEO reports 700,000 new senior patients have started GLP-1 drugs since Medicare coverage launched in July, with 70% choosing Lilly products.
Some 700,000 Medicare-eligible seniors have begun taking GLP-1 medications since federal coverage for the drug class took effect in July, Eli Lilly's chief executive disclosed, offering fresh data on how rapidly the expanded benefit is reshaping the obesity and diabetes treatment landscape.
Of that newly covered patient population, roughly 70 percent have been prescribed a Lilly-branded GLP-1 therapy, underscoring the company's commanding position in a market it shares with rival Novo Nordisk. The figures represent the most current snapshot of how Medicare's coverage expansion is translating into real-world prescriptions among older Americans.
Read more Eli Lilly CEO: One-Third of New GLP-1 Pill Users Choose Foundayo →
The disclosure signals that federal reimbursement is proving a meaningful driver of adoption, removing a financial barrier that previously kept many seniors from accessing treatments that can carry list prices of more than $1,000 per month. Analysts have broadly anticipated that Medicare coverage would unlock a substantial new patient cohort, and the early enrollment figures appear to support that thesis.
Lilly has moved aggressively to scale manufacturing capacity in anticipation of surging demand, and the Medicare numbers add weight to the company's argument that supply constraints are easing enough to meet a broader patient base. The data also carry implications for federal drug spending projections as policymakers monitor the budget impact of covering GLP-1s at scale.
Continue reading at Business News.
